Two Flagship Pioneering companies built on AI drug discovery are becoming one. Valo Health and Montai Therapeutics will merge and operate under the Valo brand, the companies said November 11. Financial terms were not disclosed.
Flagship launched Valo in 2020 with close to $100M to compress drug development timelines across oncology, neurodegenerative and cardiovascular disease. Montai started in 2022 with $50M and built a chemistry platform for immunological and respiratory conditions.
The combined pipeline starts in the clinic
The enlarged Valo will advance a pipeline led by Montai’s MTAI-1025, an oral NRF2 agonist already dosing participants in a Phase 1 trial for ulcerative colitis, plus an oral STAT6 inhibitor for atopic dermatitis. Preclinical and discovery programs round out the list.
Brian Alexander, Valo’s chief executive and a Flagship CEO-partner, will lead the merged company. Alexander said the deal gives Valo a larger pipeline and established partnerships.
Human evidence as the shared premise
Both companies organize discovery around human data rather than animal models. Montai chief executive Margo Georgiadis, also a Flagship CEO-partner, said joining Valo lets her team apply its platform to more targets across immunology and inflammation.
Valo brings a substantial partnership book. It signed a Parkinson’s disease collaboration with Merck KGaA worth up to $3B, and holds agreements with Novo Nordisk, Pfizer and contract research organization Charles River Laboratories.
Pfizer links on both sides
Montai reached Pfizer through Flagship in 2024 to find small molecules in lung cancer.
The merger continues a pattern Flagship has followed before, combining portfolio companies when their science overlaps enough to share infrastructure. It also arrives as investors press AI drug discovery companies to show clinical proof rather than platform claims. Valo and Montai will need trial readouts, not algorithms, to justify the consolidation.
